The pri­ma­ry failed. The key sec­ondary failed. But this biotech still be­lieves it can win an FDA OK in ALS

Two years af­ter the ex­ec­u­tive team at Brain­Storm Cell Ther­a­peu­tics de­cid­ed to back off a con­tro­ver­sial at­tempt to sell their stem cell ther­a­py for ALS un­der the new ‘Right to Try’ leg­is­la­tion, the biotech is back with the top-line da­ta from Phase III. And the da­ta aren’t good.

Re­searchers say the drug — with a once-pro­posed price of $300,000 — failed the pri­ma­ry end­point as well as the key sec­on­daries on dis­ease pro­gres­sion. But the ex­ec­u­tive crew still thinks it’s ap­prov­able. And in fact, the biotech al­so in­sists the FDA is ea­ger to re­view it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.